US 12,122,773 B2
Crystalline hydrate of a JAK inhibitor compound
Gene Timothy Fass, San Bruno, CA (US)
Assigned to Theravance Biopharma R&D IP, LLC, South San Francisco, CA (US)
Filed by Theravance Biopharma R&D IP, LLC, South San Francisco, CA (US)
Filed on May 31, 2023, as Appl. No. 18/326,732.
Application 18/326,732 is a continuation of application No. 17/249,375, filed on Mar. 1, 2021, granted, now 11,702,415.
Claims priority of provisional application 62/983,931, filed on Mar. 2, 2020.
Prior Publication US 2024/0025897 A1, Jan. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 9/00 (2006.01); A61P 11/06 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 9/0053 (2013.01); A61P 11/06 (2018.01); C07B 2200/13 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A crystalline hydrate of the compound of formula 1:

OG Complex Work Unit Chemistry
wherein the crystalline hydrate is Form I characterized by a powder X-ray diffraction pattern comprising diffraction peaks at 2θ values of 5.68±0.20 and 10.43±0.20.